Alpha Score of 49 reflects weak overall profile with moderate momentum, poor value, strong quality, moderate sentiment.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 1.02M | $316.03M | NEW |
| Marshall Wace | 105K | $32.75M | NEW |
| Point72 Steve Cohen | 81K | $25.13M | NEW |
| D.E. Shaw David Shaw | 8K | $2.34M | NEW |
| Hussman Investment Trust John Hussman | 4K | $1.31M | NEW |
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Earnings calendar coming soon. Subscribe to get notified when PEN reports next.
Get earnings alerts →